The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis.

Abstract

BACKGROUND:

Infliximab (IFX) and adalimumab (ADA) refer to the classic drugs to treat moderate-severe inflammatory bowel disease (IBD), which have been proven to be effective to control IBD. However, the side effects exerted by IFX and ADA should be monitored in therapies, especially the paradoxical reaction of the skin system (e.g., psoriasis). Psoriasis is recognized as the most common skin lesion, capable of significantly affecting the quality of patients' life.

METHODS:

This study searched literatures published in English language with the qualifications on PubMed, Embase, Web of Science, Google, and Geenmedical databases. Over 2 co-authors assessed the quality of the articles and extracted the data independently. The data acquired were statistically analyzed with the statistical software of Revman and Stata.

RESULTS:

The ADA Group achieved a higher incidence of psoriasis (odds ratio [OR] = 0.658, 95% confidence interval [CI] [0.471-0.919]); Females achieved a higher incidence of psoriasis than males (OR = 1.941, 95%CI [1.326-2.843], P < .05); Smoking up-regulated the incidence of psoriasis (OR = 1.679, 95%CI [1.237-2.279], P < .05); The interval of medication was over 1 year, and the interval of medication applying IFX was longer than that of the ADA Group; most cases could be relieved by using local hormone, phototherapy, or systemic hormone therapy under the strategy of biological agents.

CONCLUSIONS:

The frequency of reported in IBD exceeds those of other autoimmune diseases, and the ADA treatment for IBD is safer than IFX. Psoriasis is more common in females than in males. Smoking refers to one of risk factors of psoriasis.

• Authors: Meiqi Yang, Weixin Liu, Qiuping Deng, Zeng Liang, Qin Wang
• Journal: Medicine (Medicine (Baltimore)) Vol. 100 Issue 42 Pg. e27510 (Oct 22 2021) ISSN: 1536-5964 [Electronic] United States
• PMID: 34678884 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
• Copyright: Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Chemical References

• Gastrointestinal Agents
• Tumor Necrosis Factor Inhibitors
• Infliximab
• Adalimumab

Topics

• Adalimumab (therapeutic use)
• Gastrointestinal Agents (administration & dosage, adverse effects, therapeutic use)
• Humans
• Incidence
• Inflammatory Bowel Diseases (drug therapy, epidemiology)
• Infliximab (therapeutic use)
• Psoriasis (drug therapy, epidemiology)
• Risk Factors
• Sex Distribution
• Smokers (statistics & numerical data)
• Tumor Necrosis Factor Inhibitors (administration & dosage, adverse effects, therapeutic use)